At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
IMV IMV Inc
Halted 05-03 16:00:00 EDT
0.8225
+0.0000
0.00%
High0.8225
Low0.8225
Vol0.00
Open0.8225
D1 Closing0.8225
Amplitude0.00%
Mkt Cap9.63M
Tradable Cap8.37M
Total Shares11.71M
T/O0.00
T/O Rate0.00%
Tradable Shares10.17M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Toyota Launches IMV 0 in Thailand Providing Mobility to Make People's Lives Better through Customizability
IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and MSI-H solid tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.